20 Oct 2023 Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Marburg Vaccine in Uganda
11 Oct 2023 MinervaX Raises EUR 54M in Upsized Financing to Advance the Development of its Maternal Vaccine Against Group B Streptococcus
10 Oct 2023 Atom Bioscience Doses First Patient in Phase 2b/3 Clinical Trial of a New Treatment for Chronic Gout
08 Oct 2023 Angany announces First-in-Human Clinical Study on ANG-101, a Vaccine Candidate to Treat Cat Allergy
05 Oct 2023 Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company's Combination Vaccine Against Influenza and COVID-19
03 Oct 2023 Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
29 Sep 2023 PharmaJet Partner, Scancell, Announces Positive Data from the First Stage of its Phase 2 Trial of Advanced Melanoma DNA Vaccine delivered Needle-free
28 Sep 2023 Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer
28 Sep 2023 VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern
28 Sep 2023 New Study Shows Longhorn Vaccines and Diagnostics’ Universal Influenza Vaccine, LHNVD-105, Generates Broad and Durable Immune Responses in Animal Models
27 Sep 2023 YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine
26 Sep 2023 Longhorn Vaccines and Diagnostics Presents Data Demonstrating Neutralizing Activity of LHNVD-201 for Covid-19 and Influenza Co-Infections
20 Sep 2023 Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
20 Sep 2023 SpyBiotech Announces MHRA Clinical Trial Application Filing for SPYVLP01
19 Sep 2023 LinKinVax and Gustave Roussy Announced First Patient Dosed in Phase I/IIa Clinical Study on HPV.DCVax in HPV-positive Oropharyngeal Cancer
12 Sep 2023 Replicate Bioscience Initiates a Phase 1 Trial of its Next-Generation srRNA Vaccine
12 Sep 2023 OSE Immunotherapeutics Announces: Positive Phase 3 Data from its Cancer Vaccine in Lung Cancer Patients with Resistance to Previous Immunotherapy Published in Annals of Oncology
12 Sep 2023 Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
08 Sep 2023 BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer
08 Sep 2023 VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM
07 Sep 2023 Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate
06 Sep 2023 VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B
05 Sep 2023 Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19
05 Sep 2023 ILiAD Biotechnologies Reports First-ever Demonstration of Protection Against B. pertussis Colonization in Phase 2b Human Challenge Study of BPZE1 Vaccine
05 Sep 2023 ACM Biolabs Announces Positive Topline Results from a Phase I Trial of SARS-CoV-2 Booster Vaccine ACM-001

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up